Novo Nordisk A/S (NVO) Hemophilia-A Treatment Wins EU Panel Backing
9/20/2013 7:24:28 AM
Novo Nordisk A/S (NOVOB) won backing from a European Union advisory panel for a hemophilia A medicine, a step forward in the Danish company’s plan to expand treatment offerings for the blood-clotting disorder. Turoctocog alfa was recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use, Novo Nordisk said in an e-mailed statement today. The European Commission, the EU’s executive arm, usually follows the panel’s recommendation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by